Jubilant Pharmova reported a significant increase in its financial performance for FY 2026. Revenue from operations grew by 14% to ₹82,796 Million, driven by strong growth across its key business segments, particularly the CDMO Sterile Injectables business. Profitability also saw a healthy increase, with Normalised PAT growing by 7%, reflecting improved operating performance and strategic initiatives.
Strong Financial Performance in FY26
Jubilant Pharmova announced robust financial results for the fiscal year ended March 31, 2026. The company’s revenue from operations saw a substantial increase of 14%, reaching ₹82,796 Million, up from ₹72,345 Million in the previous fiscal year. This growth was broad-based across its key businesses, notably Radiopharma, Allergy Immunotherapy, CRDMO, Generics, and especially the CDMO Sterile Injectables business, where the operationalization of its new Line 3 facility contributed significantly to incremental revenue.
Profitability and Segment Highlights
EBITDA for the year grew by 8% to ₹13,255 Million, despite a dip in the Radiopharmaceuticals business due to lower SPECT product production at its Montreal facility. The company expects EBITDA margins to improve from the second half of FY27. Normalised Profit After Tax (PAT) increased by 7% to ₹4,424 Million, attributed to improved operating performance across its business segments. The company also proposed a final dividend of ₹5 per equity share, subject to shareholder approval.
Strategic Progress and Outlook
Jubilant Pharmova highlighted its strategic progress, translating intent into acceleration, strategy into structure, and resilience into sustained growth, anchored in its theme of Velocity, Agility, and Momentum. The company has significantly strengthened its operational foundation and is well-positioned to capitalize on emerging global healthcare opportunities. Key business segments like Radiopharma, CDMO Sterile Injectables, CRDMO, Generics, and Allergy Immunotherapy all demonstrated positive growth drivers and progress towards their respective strategic priorities and Vision 2030 targets.
Source: BSE
